NCT06173895

A Relative Bioavailability Study of LY3454738 in Healthy Participants

A Phase 1, Open-Label Study to Determine the Relative Bioavailability of LY3454738 in Healthy Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The main purpose of this study is to look at the amount of the study drug, LY3454738 that gets into the blood stream and how long it takes the body to get rid of it when given under the skin comparing a test formulation versus a reference formulation in healthy participants. The study will also evaluate the safety and tolerability of LY3454738 and information about any side effects experienced will be collected. For each participant, the total duration of the study will be approximately up to 17 weeks, including screening period.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	LY3454738	Administered subcutaneously (SC)

Timeline

• Start date: 2024-01-12
• Primary completion: 2024-05-02
• Completion: 2024-05-02
• First posted: 2023-12-18
• Last updated: 2024-05-30

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study